The Court, in infringement proceedings brought by Novartis against Actavis for marketing generic Valsartan, held that the assessment of infringement had to be made as of the time of infringement, not as of the priority date. This is the first decision in years in Norway taking a position on this issue.
The judgement also deals with the scope of Novartis SPC for Valsartan, which the Court held to protect both mono products and combination products with Valsartan and HCTZ.
Click here for the full text of this case.
A full summary of this case has been published on Kluwer IP Law.
________________________
To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.
